RecruitingPhase 1Phase 2NCT05371145

Carnosine for Peripheral Arterial Disease Patients

Carnosine for Peripheral Arterial Disease Patients (Car-PAD)

Sponsor

Shahid Baba

Enrollment

20 participants

Start Date

Mar 1, 2023

Study Type

INTERVENTIONAL

Conditions

Peripheral Arterial Disease

Summary

Oral supplementation of L-carnosine will increase muscle carnosine, stabilize HIF1-alpha promote angiogenesis, and thus improve the functioning of lower extremities in PAD patients.

Eligibility

Sex: MALEMin Age: 50 YearsMax Age: 80 Years

Inclusion Criteria6

Male subjects more than >50 to <80 years of age.
White or African American race.
English Speaking.
ABI 0.4-< 0.60
Willing to comply with protocol requirements.
Able to provide informed consent. -

Exclusion Criteria15

Subjects with HIV, hepatitis, significant liver disease, active infection, anemia, organ transplant, renal disease requiring dialysis, lung disease requiring oxygen, significant congenital heart disease, cancer of any type, and untreated thyroid disease.
Diagnosis of carnosinemia.
Known allergy to L-carnosine or meat.
Presence of a pacemaker.
Obesity from a known genetic defect.
Dementia.
Critical limb ischemia with below or above knee amputations.
Foot ulcers.
Major amputations.
Participating in other clinical trials.
End stage renal disease.
Presence of significant injury within 30 days before enrollment.
Prisoners.
Any metallic implants.
Poorly controlled diabetes (HbA1C >9%) -